Gain Therapeutics (GANX) Invested Capital (2020 - 2025)
Gain Therapeutics (GANX) has 6 years of Invested Capital data on record, last reported at $6.0 million in Q3 2025.
- For Q3 2025, Invested Capital fell 33.15% year-over-year to $6.0 million; the TTM value through Sep 2025 reached $6.0 million, down 33.15%, while the annual FY2024 figure was $7.4 million, 41.33% down from the prior year.
- Invested Capital reached $6.0 million in Q3 2025 per GANX's latest filing, up from $3.8 million in the prior quarter.
- Across five years, Invested Capital topped out at $44.5 million in Q1 2021 and bottomed at $3.8 million in Q2 2025.
- Average Invested Capital over 5 years is $18.9 million, with a median of $12.7 million recorded in 2023.
- Peak YoY movement for Invested Capital: surged 63122.01% in 2021, then plummeted 67.87% in 2025.
- A 5-year view of Invested Capital shows it stood at $34.9 million in 2021, then plummeted by 45.63% to $19.0 million in 2022, then tumbled by 33.13% to $12.7 million in 2023, then crashed by 41.33% to $7.4 million in 2024, then dropped by 18.99% to $6.0 million in 2025.
- Per Business Quant database, its latest 3 readings for Invested Capital were $6.0 million in Q3 2025, $3.8 million in Q2 2025, and $5.9 million in Q1 2025.